univers coverag
calendar event
medic meet endocrin societi canadian academi patholog american
chemic societi intern confer ureagenesi defect
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
bottom line recent start project analyz trajectori valu oncolog drug
launch ultim goal estim valu drug reliabl
current patient-bas forecast approach first part project publish
previou note link summar indic approv revenu trend compani
particip categori last year note examin predict
cancer drug revenu explor differ factor might suggest higher lower revenu
potenti compar categori whole object assess reliabl
forecast consid whether approach estim valu product might
reliabl tradit patient-bas forecast
perform cancer drug launch last year polar blockbust
launch major rel modest commerci outcom
earli launch trajectori highli predict maximum potenti
initi launch trajectori consist throughout year sale ramp-up year
pharma better
best-sel cancer drug reli us sale
bottom line omnibu spend bill due morn though includ
obamacar stabil measur share subsidi csr given partisan
disput around abort possibl obamacar measur may appear separ measur
senat later week like fashion propos senat lamar alexand bill
could includ modif medicar part donut hole closur senat roy blunt r-mo
state believ cbo underestim cost save unclear much support
amend time floor vote omnibu bill expect hous thursday
fast track senat bill friday govern fund run obamacar stabil
measur impact mp coverag estim hix exposur
op op could re-up exposur retrench given profit
issu exposur facil remain low-singl mid-singl digit ebitda obamacar
stabil impact op mp op op lpnt mp
omnibu bill expect today though exclud obamacar stabil measur
obamacar stabil measur may reappear separ bill later week senat
hix stabil expect reduc premium impact
lesser extent
within facil lack fund also structur headwind beyond -- enjoy
low- mid-singl digit ebitda upsid exchang
previou csr analysi avail follow link
oasi show best class efficaci safeti get pt
bottom line top-lin data oasi studi etrasimod moderate-to-sever
ulcer colitis/uc came better expect hit primari secondari
endpoint surprisingli mg etrasimod also achiev underpow hurdl clinic
remiss measur total mayo score scale although
management discuss two incid asymptomat atrioventricular av block transient natur
resolv may give investor paus believ today data distinguish etrasimod
favor versu phosphat receptor modul term
efficaci safeti go forward investor anticip addit data futur medic
meet well arena futur plan uc crohn diseas autoimmun
indic receptor modul benefici link reiter op
increas pt previous
etrasimod achiev stat sig improv primari endpoint partial mayo score pm
oasi enrol difficult-to-treat pt use tm mg etrasimod cohort still
although safeti profil mostli favor investor focu like linger cardiac safeti
rais po previous posit data opex also adjust assum intensifi
develop plan etrasimod
encor data increment ovat conf call et
bottom line close elgx put press releas announc posit result
encor analysi polym endovascular aneurysm repair evar use ovat
abdomin stent graft increment posit -- -albeit margin one view -- -for
ovat product line one bright spot elgx recent quarter grow
help mitig degre headwind elgx afx intern nellix
busi -- -both declin ovat use come expens afx cannib
long run like good thing given ovat come higher price point vs afx
 ovat broader applic vs afx nich indic clear us yet kind
quantifi impact might near-term number one sever anticip
dataset updates/present elgx portfolio gener see catalyst-weak
limit year estim upsid potenti view bigger needle-mov ovat
franchis like ovat alto elgx second gen devic expand treatment
complex abdomin aortic aneurysm aaa patient -- -an increment market opportun accord
management current model assum us ww ovat revenu acceler
growth assum ovat alto approv
compani host confer call et tuesday
encor one two anticip dataset ovat
phase result essenti de-risk rais pt
 methodolog dcf cash flow use wacc
bottom line rais sale estim
base posit phase data bunionectomi hernia repair announc earlier today
data support potenti approv post oper pain via instil data also make us
optimist total knee arthroplasti tka phase studi result expect rais
dcf deriv price target reiter op rate continu see upsid
nerv block indic post oper pain expect phase data includ
risk-adjust sale model current potenti ou partnership current
includ valu model potenti commerci partnership us current
assum heron market base manag comment rule potenti
partnership look result phase tka instil breast
augment instil nerv block addit visibl potenti partnership
continu ramp chemo induc nausea vomit franchis
demonstr posit data two pain model well toler safeti profil
path approv instil essenti de-risk
phase data allow commerci market opioid spare data
capit requir remain concern ahead potenti resourc intens launch
bottom line view appoint cole lannum posit senior vice presid
investor relat ir increment posit develop zbh evolv turnaround
announc come week investor session aao
confer ceo bryan hanson indic sever senior level posit would fill
come week includ new head oper ir strategi -- -all part ceo hanson goal
establish cultur account improv execut start top think mr
lannum good choic ir role long-tim wall street ir veteran strong buy-
side sell-sid relationship highli recogn track record med-tech day
vice-president ir covidien tyco healthcar nine year interact frequent
cover covidien prior mp acquisit view play critic posit role
help manag buy-sid sell-sid expect commun controversial/compl
covidien mr lannum ir mp -- -where interact
believ mr lannum experi gener met enthusiasm invest commun
time prove import step help restor manag credibl
panorama open new vista eylea impact depend fine print
averag price-to-earnings p/ dcf methodolog
bottom line morn regeneron announc result panorama trial
eylea patient moder non-prolif diabet retinopathi npdr met
week primari endpoint result came sooner anticip posit
anticip least compani first press releas top-lin result
previous note see preview note ad dr eylea outlook boost
revenu ep estim result open signific new market eylea could
expand address pool patient broader diabet eye diseas indic
compar current dme-onli indic anticip us approv launch
indic eylea alreadi includ us sale estim regeneron
grow overal us eylea sale estim
higher recent consensu estim higher
recent consensu suggest consensu valu increment indic
reiter op rate pt
bottom line morn announc harri connick jr wife celebr
endors cologuard next year believ expect street elev
celebr endors stock pullback still appear aggress us believ street
look celebr significantli broader appeal one could elev cologuard
brand via market effort harri connick jr wife also breast cancer survivor
unlik drive level market impact vs like georg clooney age yr hugh
jackman age yr ophrah winfrey age yr smith age yr potenti
assum coverag nda submiss ibs-c
final ncd posit advanc cancer test path valu creation
expect submit new drug applic nda ali march prioriti
previous guid remain track expect advisori committe meet
adcom amikacin liposom inhal suspens ali refractori nontubercul
mycobacteri lung infect ntm caus mycobacterium avium complex
stock come investor question efficaci long-term durabl
approv believ fda panelist could view posit
extens studi data refractori ntm patient favor
believ discuss point may even consid possibl ali front-lin
therapi ahead guidelin base therapi fda-approv
addit ali data american thorac societi meet may
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
burosumab recent receiv posit eu chmp decis x-link
hypophosphataemia xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
pdufa date fda advisori committe meet expect
bold ph i/ii x-link myotubular myopathy/xlmtm
audent expect announc updat phase i/ii aspiro data
possibl american societi gene cell therpay confer may
also expect phase i/ii valen data possibl european societi
pediatr gastroenterolog hepatolog nutrit meet may
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
amicu enzyme-chaperon candid gener promis clinic
data thu far ph i/ii studi
management recent announc studi enrol addit pt gain insight
drug clinic profil
meanwhil observ studi potenti run-
upcom ph studi could provid import natur histori compar data
on-going ph i/ii studi
amicu meet regul updat
earli specul management believ rang outcom possibl
meet remain laser-focus get fastest approv pathway
model alreadi reflect earli launch possibl ascrib probabl success
po market vs po launch
compani anticip report ph ii proof-of-concept data
management state observ reduct level -- marker glycem control
dose depend
compani anticip observ dose respons biomark reflect
drug mechan action
goal would posit agent line difficult-to-treat patient use
glycem control compani see potenti market appli
probabl success
model gross sale
sourc leerink research compani inform factset price prior day
fda adcom joint meet blood product microbiolog devic
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia asnd
brief document eversens pma medic devic adcom
fda adcom clinic chemistri clinic toxicolog devic panel
medic devic link note
pdufa opdivo yervoy intermedi poor risk renal cell carcinoma
fda adcom peripher central nervou system drug
fda adcom endocrinolog metabol drug
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
 canadian academi patholog
intern confer ureagenesi defect
societi surgic oncolog
american academi osteopathi
societi gynecolog oncolog
intern societi amyloidosi
american colleg medic genet genom
intern societi heart lung transplant
societi american gastrointestin endoscop surgeon
american societi laser medicin surgeri
european associ studi liver
american societi cataract refract surgeri
american associ cancer research arql tsro
american head neck societi combin otolaryngolog spring meet
american societi androlog
european congress clinic microbiolog infecti diseas
american academi neurolog
nation foundat infecti diseas annual confer vaccin
american societi aesthet plastic surgeri
american congress obstetrician gynecologist
american associ neurolog surgeon
american associ thorac surgeri
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo rewind
biopharma -- flash highlight invokana fda warn puls call modest impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco -- flash inclisiran lesson fourier/odyssey may better
mdco anoth step forward cubist vabomer approv pt outperform
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await full
biopharma ada day takeaway healthcar focu canva event
biopharma -- flash highlight invokana fda warn puls call modest impact
biopharma -- flash jardianc win lose wake invokana safeti
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market perform
esrx aggress price loss competit market pt market perform
hcit distribut fda take step improv competit distributor near trough
 dupix price valu money new outperform
tsro zejula price prompt model valuat updat pt lower market
 medacorp call gener posit sinuva reimburs prospect
biopharma name shame california latest strategi rein drug price
 price sensit analysi show path share upsid pt outperform
healthcar distribut suppli chain preview price volum trend appear
hcit distribut outlin possibl drug price polici draconian
fear
hcit distribut brand inflat top show deceler y/i
cautiou
 elast demand consist reduc price drive volum growth
novob dc disappoint oral sema currenc price fear bake
 respit price yet friendli hill fda could
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 patent fall hurdl humira cut like pipelin loom market
achn recap increment advanc patent complement progress
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win market
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year outperform
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 management highlight robust partnership program pt
 add cscc respons diseas boost /sni partnership
 increas pt takeda collabor stock weak offer oppti
 atop dermat still without ped leerink dupix
derm survey
 discuss deep dive alks/itci test fda flexibl alny/ion
ttr amyloidosi physician survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
 analyst event best idea
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey focus
nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer assist
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup procedure/
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri bigfoot brink disrupt model
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
